Sirtex Medical Release: Study Reveals Survival Benefit for Patients with Inoperable Hepatocellular Carcinoma (HCC) treated with a Unique Combination of Radioactive Microspheres and Standard-of-Care Systemic Therapy

CHICAGO--(BUSINESS WIRE)--A unique combination of liver targeted radioactive microspheres (SIR-Spheres) and a standard-of-care systemic agent (Sorafenib) appears to confer a survival benefit for patients with inoperable primary hepatocellular cancer (HCC) including those with disease that has spread outside the liver, according to the results of a prospective clinical study presented today at the 46th American Society of Clinical Oncology (ASCO) conference. The multi-center Phase II study was conducted by the Asia Pacific Hepatocellular Carcinoma Trials Group (AHCC) headed by Professor Pierce Chow, Senior Consultant, Singapore General Hospital and Visiting Senior Consultant, National Cancer Center Singapore.

Back to news